OasisLMS

Welcome to the second episode this week in our triple header of late breaking clinical trials coverage from Heart Rhythm 2026 in Chicago. Host Christopher C Cheung, MD, MPH, FHRS is joined by Mihail G. Chelu, MD, PhD, FHRS and Derek Chew, MD, MS, FHRS for a conversation in Chicago. The LEAP2 trial, a first-in-human chronic feasibility study presented at Heart Rhythm 2026, evaluated a novel leadless pacemaker designed for conduction system pacing to more closely replicate physiologic cardiac activation. Early results from this small cohort demonstrated high implantation success, reliable device performance, and effective pacing of the heart’s native conduction pathways through short-term follow-up. These findings highlight the potential of leadless conduction system pacing as an innovative alternative to traditional pacing strategies, pending further long-term data

Describe the principles and clinical rationale for conduction system pacing and how it differs from traditional right ventricular pacing. 

Evaluate early safety and performance outcomes of novel leadless pacemaker systems designed for physiologic pacing. 

Assess the potential clinical implications and future role of leadless conduction system pacing technologies in patients requiring permanent pacing.

Podcast Contributors

Christopher C Cheung, MD, MPH, FHRS
Mihail G. Chelu, MD, PhD, FHRS
Derek Chew, MD, MS, FHRS

All relevant financial relationships have been mitigated.

Host and Contributor Disclosure(s):

C. Cheung

D. Chew

Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):

S. Sailor: No relevant financial relationships with ineligible companies to disclose.